In the Netherlands, patients with a rare oncogenic mutation can only be treated in an academic, designated centre for rare (defined as <5% incidence in NSCLC, e.g., ALK) driver mutations in NSCLC, while patients with a classical EGFR ex19del or EGFR ex21 L858R can be treated in all Dutch hospitals. The gene discussed is ALK; the disease is non-small cell lung carcinoma.